title: Norfloxacin and Salmonella excretion in acute gastroenteritis--a 6-month follow-up study.
abstract: In a controlled, randomized, double-blind study, 100 patients (66 women, 34 men; age 18-69 years) with acute salmonellosis were treated with norfloxacin (400 mg) or placebo tablets twice daily for 10 days to compare the effects on the excretion time of salmonella bacteria. In all patients salmonellae were detected in the stools before the start of treatment. The follow-up included 6 stool cultures after the start of treatment: day 3-4, day 12-14, and 4 times during 1-6 months. At 3-4 days there were 98% non-excretors in the norfloxacin group (46/47 patients) compared to 38% (17/45) in the placebo group (p < 0.001). The cumulative 6-month elimination rate in norfloxacin patients at 3-4 days was 72%, which was significantly (p = 0.0001) greater than the 31% in the placebo patients. However, there was no significant difference in the proportion of non-excretors or the elimination rate between the 2 groups at the following visits. Only one patient had an adverse event resulting in discontinuation of the treatment. We conclude that norfloxacin treatment for 10 days decreased the excretion of salmonella bacteria during the first week, but there was no difference in excretion rates 1-6 months after treatment initiation in the treatment versus placebo group.
authors.affiliation: Community Health Centre of the City of Tampere, Finland.
authors.forename: T
authors.initials: T
authors.lastname: Pitkäjärvi
authors.forename: E
authors.initials: E
authors.lastname: Kujanne
authors.forename: I
authors.initials: I
authors.lastname: Sillantaka
authors.forename: J
authors.initials: J
authors.lastname: Lumio
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002353:Carrier State / Q000453:epidemiology; D004311:Double-Blind Method; D005243:Feces / Q000382:microbiology*; D005260:Female; D005500:Follow-Up Studies; D005759:Gastroenteritis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009643:Norfloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D011379:Prognosis; D012480:Salmonella Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000890:Anti-Infective Agents; D009643:Norfloxacin